pmid
stringlengths 8
12
| sentence
stringlengths 59
1.08k
| cancer_type
stringclasses 3
values | gene
dict | cancer
dict | CGE
stringclasses 2
values | CCS
stringclasses 3
values | PT
stringclasses 3
values | IGE
stringclasses 4
values | expression_change_keyword_1
dict | expression_change_keyword_2
dict |
|---|---|---|---|---|---|---|---|---|---|---|
15138597.s0 | Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients. | breast | {
"name": "leptin",
"pos": [
47,
52
]
} | {
"name": "breast cancer",
"pos": [
90,
102
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "expression",
"pos": [
10,
19
],
"type": "Gene_expression"
} | {
"name": "increase",
"pos": [
54,
61
],
"type": "Positive_regulation"
} |
15138597.s0 | Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients. | breast | {
"name": "leptin",
"pos": [
47,
52
]
} | {
"name": "breast cancer",
"pos": [
90,
102
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increase",
"pos": [
54,
61
],
"type": "Positive_regulation"
} |
15138597.s8 | Patients with breast cancer showed enhanced blood plasma concentrations of progesterone and estradiol, and enhanced tissue levels of ER and PGR associated with increased leptin levels. | breast | {
"name": "PGR",
"pos": [
140,
142
]
} | {
"name": "breast cancer",
"pos": [
14,
26
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "enhanced",
"pos": [
107,
114
],
"type": "Positive_regulation"
} |
15138597.s8 | Patients with breast cancer showed enhanced blood plasma concentrations of progesterone and estradiol, and enhanced tissue levels of ER and PGR associated with increased leptin levels. | breast | {
"name": "leptin",
"pos": [
170,
175
]
} | {
"name": "breast cancer",
"pos": [
14,
26
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increased",
"pos": [
160,
168
],
"type": "Positive_regulation"
} |
19995430.s13 | We conclude that 13q34 amplification may be of relevance in tumor progression of basal-like breast cancers by inducing overexpression of CUL4A and TFDP1, which are both important in cell cycle regulation. | breast | {
"name": "CUL4A",
"pos": [
137,
141
]
} | {
"name": "breast cancers",
"pos": [
92,
105
]
} | increased | normalTOcancer | causality | unchanged | {
"name": "overexpression",
"pos": [
119,
132
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
119,
132
],
"type": "Positive_regulation"
} |
17872978.s0 | Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility. | ovarian | {
"name": "Myosin II co-chaperone general cell UNC-45",
"pos": [
0,
41
]
} | {
"name": "ovarian cancer",
"pos": [
77,
90
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpression",
"pos": [
43,
56
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
43,
56
],
"type": "Positive_regulation"
} |
17872978.s6 | Elevation of GC UNC-45 levels by ectopic expression enhanced the rate of ovarian cancer cell proliferation, whereas siRNA knockdown of GC UNC-45 suppressed proliferation without altering myosin II levels. | ovarian | {
"name": "GC UNC-45",
"pos": [
13,
21
]
} | {
"name": "ovarian cancer",
"pos": [
73,
86
]
} | increased | normalTOcancer | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "Elevation",
"pos": [
0,
8
],
"type": "Positive_regulation"
} |
17872978.s6 | Elevation of GC UNC-45 levels by ectopic expression enhanced the rate of ovarian cancer cell proliferation, whereas siRNA knockdown of GC UNC-45 suppressed proliferation without altering myosin II levels. | ovarian | {
"name": "GC UNC-45",
"pos": [
135,
143
]
} | {
"name": "ovarian cancer",
"pos": [
73,
86
]
} | decreased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "knockdown",
"pos": [
122,
130
],
"type": "Negative_regulation"
} |
17872978.s9 | Knockdown of GC UNC-45 reduced the spreading ability of ovarian cancer cells whereas it was enhanced by GC UNC-45 overexpression. | ovarian | {
"name": "GC UNC-45",
"pos": [
13,
21
]
} | {
"name": "ovarian cancer",
"pos": [
56,
69
]
} | decreased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "Knockdown",
"pos": [
0,
8
],
"type": "Negative_regulation"
} |
17872978.s9 | Knockdown of GC UNC-45 reduced the spreading ability of ovarian cancer cells whereas it was enhanced by GC UNC-45 overexpression. | ovarian | {
"name": "GC UNC-45",
"pos": [
104,
112
]
} | {
"name": "ovarian cancer",
"pos": [
56,
69
]
} | increased | normalTOcancer | causality | unidentifiable | {
"name": "overexpression",
"pos": [
114,
127
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
114,
127
],
"type": "Positive_regulation"
} |
17872978.s10 | In sum, these findings implicate elevated GC UNC-45 protein expression in ovarian carcinoma proliferation and metastasis. | ovarian | {
"name": "GC UNC-45 protein",
"pos": [
42,
58
]
} | {
"name": "ovarian carcinoma",
"pos": [
74,
90
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "expression",
"pos": [
60,
69
],
"type": "Gene_expression"
} | {
"name": "elevated",
"pos": [
33,
40
],
"type": "Positive_regulation"
} |
19438741.s8 | In summary, in patients with primary ovarian cancer, overexpression of MRP1 is an adverse marker for patient outcome and cancer aggressiveness. | ovarian | {
"name": "MRP1",
"pos": [
71,
74
]
} | {
"name": "ovarian cancer",
"pos": [
37,
50
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "overexpression",
"pos": [
53,
66
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
53,
66
],
"type": "Positive_regulation"
} |
19048115.s0 | Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. | ovarian | {
"name": "NF1",
"pos": [
17,
19
]
} | {
"name": "ovarian serous carcinomas",
"pos": [
50,
74
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "defects",
"pos": [
22,
28
],
"type": "Negative_regulation"
} |
19048115.s0 | Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. | ovarian | {
"name": "Neurofibromin 1",
"pos": [
0,
14
]
} | {
"name": "ovarian serous carcinomas",
"pos": [
50,
74
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "defects",
"pos": [
22,
28
],
"type": "Negative_regulation"
} |
20075391.s4 | We tested the in vivo effects of GSK690693 in Lck-MyrAkt2 transgenic mice that develop lymphomas, heterozygous Pten(+/-) knockout mice that exhibit endometrial tumors, and TgMISIIR-TAg-DR26 mice that develop ovarian carcinomas, all of which exhibit hyperactivation of Akt. | ovarian | {
"name": "Akt",
"pos": [
268,
270
]
} | {
"name": "ovarian carcinomas",
"pos": [
208,
225
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "hyperactivation",
"pos": [
249,
263
],
"type": "Positive_regulation"
} |
12481432.s10 | Overall, these results implicate inhibition of DNA-PK as a component of TLK286 cytotoxicity and provide a rationale for its use in the clinical management of cisplatin-resistant ovarian cancer. | ovarian | {
"name": "DNA-PK",
"pos": [
47,
52
]
} | {
"name": "ovarian cancer",
"pos": [
178,
191
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "inhibition",
"pos": [
33,
42
],
"type": "Negative_regulation"
} |
||
14694444.s0 | Antisense blocking of BRCA1 enhances sensitivity to plumbagin but not tamoxifen in BG-1 ovarian cancer cells. | ovarian | {
"name": "BRCA1",
"pos": [
22,
26
]
} | {
"name": "ovarian cancer",
"pos": [
88,
101
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "blocking",
"pos": [
10,
17
],
"type": "Negative_regulation"
} |
||
14694444.s1 | Previous studies have shown that reduction in BRCA1 mRNA and protein can result in increased proliferation of BG-1 ovarian cancer cells in both in vitro and in vivo conditions, suggesting that BRCA1 may normally act as a growth inhibitor in these cells. | ovarian | {
"name": "BRCA1 mRNA",
"pos": [
46,
55
]
} | {
"name": "ovarian cancer",
"pos": [
115,
128
]
} | decreased | normalTOcancer | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "reduction",
"pos": [
33,
41
],
"type": "Negative_regulation"
} |
20309881.s0 | Loss of MKK4 expression in ovarian cancer: a potential role for the epithelial to mesenchymal transition. | ovarian | {
"name": "MKK4",
"pos": [
8,
11
]
} | {
"name": "ovarian cancer",
"pos": [
27,
40
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "expression",
"pos": [
13,
22
],
"type": "Gene_expression"
} | {
"name": "Loss",
"pos": [
0,
3
],
"type": "Negative_regulation"
} |
20309881.s5 | MKK4 gene knockdown in MDAH 2774 cells over-expressing MKK4 increased invasion activity. | ovarian | {
"name": "MKK4",
"pos": [
55,
58
]
} | {
"name": "MDAH 2774",
"pos": [
23,
31
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "over-expressing",
"pos": [
39,
53
],
"type": "Gene_expression"
} | {
"name": "over-expressing",
"pos": [
39,
53
],
"type": "Positive_regulation"
} |
20309881.s7 | Interestingly, we found that MKK4 upregulation caused downregulation of phosphorylated NF-κB and Twist, as well as upregulation of E-cadherin, in TOVG-21G and SKOV3 cells. | ovarian | {
"name": "MKK4",
"pos": [
29,
32
]
} | {
"name": "SKOV3",
"pos": [
159,
163
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "upregulation",
"pos": [
34,
45
],
"type": "Positive_regulation"
} |
||
20309881.s7 | Interestingly, we found that MKK4 upregulation caused downregulation of phosphorylated NF-κB and Twist, as well as upregulation of E-cadherin, in TOVG-21G and SKOV3 cells. | ovarian | {
"name": "E-cadherin",
"pos": [
131,
140
]
} | {
"name": "SKOV3",
"pos": [
159,
163
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "upregulation",
"pos": [
115,
126
],
"type": "Positive_regulation"
} |
||
20309881.s10 | This promotes Twist over-expression, resulting in E-cadherin downregulation that induces EMT in ovarian cancer. | ovarian | {
"name": "E-cadherin",
"pos": [
50,
59
]
} | {
"name": "ovarian cancer",
"pos": [
96,
109
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "downregulation",
"pos": [
61,
74
],
"type": "Negative_regulation"
} |
||
11150789.s6 |
From these 23 patients, 18 pts were referred for suspected recurrence of ovarian carcinoma: occult recurrence (OR) defined by an increase in serum CA-125 levels with negative conventional imaging (13 pts) or equivocal aspect at conventional imaging (5 pts). | ovarian | {
"name": "CA-125",
"pos": [
147,
152
]
} | {
"name": "ovarian carcinoma",
"pos": [
73,
89
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increase",
"pos": [
129,
136
],
"type": "Positive_regulation"
} |
17470361.s6 | We also found that: (1) luciferase activity mediated by the VEGF reporter containing a mutation of the HIF-1 binding site was much lower than that of the reporter containing a wild-type HIF-1 binding site in ovarian cancer cells, thus confirming that HIF-1 is a major transcriptional regulator of VEGF expression; and that (2) CDDP greatly inhibited VEGF reporter activity containing the wild-type but not the mutant HIF-1 binding site. | ovarian | {
"name": "VEGF",
"pos": [
350,
353
]
} | {
"name": "ovarian cancer",
"pos": [
208,
221
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "inhibited",
"pos": [
340,
348
],
"type": "Negative_regulation"
} |
||
17470361.s11 | These results suggest a novel mechanism of CDDP's anti-tumor activity in ovarian cancer cells via HIF-1 expression and VEGF transcriptional activation. | ovarian | {
"name": "VEGF",
"pos": [
119,
122
]
} | {
"name": "ovarian cancer",
"pos": [
73,
86
]
} | increased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "activation",
"pos": [
140,
149
],
"type": "Positive_regulation"
} |
11753647.s3 | Loss of this 42-bp sequence was associated with increased ERCC1 mRNA expression, in an assessment of 121 ovarian cancer specimens (p2<10(-6)). | ovarian | {
"name": "ERCC1 mRNA",
"pos": [
58,
67
]
} | {
"name": "ovarian cancer",
"pos": [
105,
118
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "expression",
"pos": [
69,
78
],
"type": "Gene_expression"
} | {
"name": "increased",
"pos": [
48,
56
],
"type": "Positive_regulation"
} |
16230405.s3 | We report that elevated expression of LPAAT-beta was associated with reduced survival in ovarian cancer and earlier progression of disease in ovarian and endometrial cancer. | ovarian | {
"name": "LPAAT-beta",
"pos": [
38,
47
]
} | {
"name": "ovarian cancer",
"pos": [
89,
102
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "expression",
"pos": [
24,
33
],
"type": "Gene_expression"
} | {
"name": "elevated",
"pos": [
15,
22
],
"type": "Positive_regulation"
} |
16230405.s5 | Inhibition of LPAAT-beta also enhanced the survival of mice bearing ovarian tumor xenografts. | ovarian | {
"name": "LPAAT-beta",
"pos": [
14,
23
]
} | {
"name": "ovarian tumor",
"pos": [
68,
80
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "Inhibition",
"pos": [
0,
9
],
"type": "Negative_regulation"
} |
||
20505730.s7 | Consistently, loss of CD95 in mouse models of ovarian cancer and liver cancer reduces cancer incidence as well as the size of the tumours. | ovarian | {
"name": "CD95",
"pos": [
22,
25
]
} | {
"name": "ovarian cancer",
"pos": [
46,
59
]
} | decreased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "loss",
"pos": [
14,
17
],
"type": "Negative_regulation"
} |
11926891.s10 | Osteopontin levels in plasma were significantly higher (P<.001) in 51 patients with epithelial ovarian cancer (486.5 ng/mL) compared with those of 107 healthy controls (147.1 ng/mL), 46 patients with benign ovarian disease (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL). | ovarian | {
"name": "Osteopontin",
"pos": [
0,
10
]
} | {
"name": "epithelial ovarian cancer",
"pos": [
84,
108
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "levels",
"pos": [
12,
17
],
"type": "Gene_expression"
} | {
"name": "higher",
"pos": [
48,
53
],
"type": "Positive_regulation"
} |
15297183.s6 | Under normoxic conditions, treatment of both ovarian cancer cell lines with dmPGE(2) resulted in a significant increase in VEGF expression but had no effect on HIF-1alpha. | ovarian | {
"name": "VEGF",
"pos": [
123,
126
]
} | {
"name": "ovarian cancer",
"pos": [
45,
58
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
128,
137
],
"type": "Gene_expression"
} | {
"name": "increase",
"pos": [
111,
118
],
"type": "Positive_regulation"
} |
||
12576450.s11 | Consequently, Id-1 inhibition in the future might be of benefit for patients with ovarian cancer. | ovarian | {
"name": "Id-1",
"pos": [
14,
17
]
} | {
"name": "ovarian cancer",
"pos": [
82,
95
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "inhibition",
"pos": [
19,
28
],
"type": "Negative_regulation"
} |
||
15867372.s1 | The overexpression of the colony-stimulating factor-1(CSF-1) by epithelial ovarian cancer cells enhances invasiveness and metastatic properties, contributing to the poor prognosis of the patients. | ovarian | {
"name": "colony-stimulating factor-1",
"pos": [
26,
52
]
} | {
"name": "epithelial ovarian cancer",
"pos": [
64,
88
]
} | increased | normalTOcancer | causality | unchanged | {
"name": "overexpression",
"pos": [
4,
17
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
4,
17
],
"type": "Positive_regulation"
} |
15867372.s1 | The overexpression of the colony-stimulating factor-1(CSF-1) by epithelial ovarian cancer cells enhances invasiveness and metastatic properties, contributing to the poor prognosis of the patients. | ovarian | {
"name": "CSF-1",
"pos": [
54,
58
]
} | {
"name": "epithelial ovarian cancer",
"pos": [
64,
88
]
} | increased | normalTOcancer | causality | unchanged | {
"name": "overexpression",
"pos": [
4,
17
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
4,
17
],
"type": "Positive_regulation"
} |
15867372.s4 | CSF-1 overexpression in Hey cells was found to associate with increased invasiveness, motility, urokinase activity, and virulence of tumorigenicity, compared with NOSE.1 cells, which expressed little CSF-1. | ovarian | {
"name": "CSF-1",
"pos": [
0,
4
]
} | {
"name": "Hey",
"pos": [
24,
26
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "overexpression",
"pos": [
6,
19
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
6,
19
],
"type": "Positive_regulation"
} |
15867372.s11 | These data suggest that GAPDH binding to CSF-1 ARE sequence prevents CSF-1 mRNA decay and subsequent down-regulation of CSF-1 protein translation, leading to CSF-1 overexpression and increased metastatic properties seen in ovarian cancer. | ovarian | {
"name": "CSF-1",
"pos": [
158,
162
]
} | {
"name": "ovarian cancer",
"pos": [
223,
236
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "overexpression",
"pos": [
164,
177
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
164,
177
],
"type": "Positive_regulation"
} |
17352242.s8 | The MMP-9 levels decreased in a time-dependent manner (3, 8, 24 h) and the addition of anti-IL-6 antibodies to SKOV-3 cell cultures significantly decreased their capacity to secrete MMP-9, particularly after 8 h of incubation. | ovarian | {
"name": "MMP-9",
"pos": [
4,
8
]
} | {
"name": "SKOV-3",
"pos": [
111,
116
]
} | decreased | unidentifiable | {
"name": "levels",
"pos": [
10,
15
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
17,
25
],
"type": "Negative_regulation"
} |
||
20878528.s8 | In the parental HEY cell line, additional treatment with the PPARγ ligands led to an increased protein expression of DR5 and a further decline of XIAP expression. | ovarian | {
"name": "DR5",
"pos": [
117,
119
]
} | {
"name": "HEY",
"pos": [
16,
18
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
103,
112
],
"type": "Gene_expression"
} | {
"name": "increased",
"pos": [
85,
93
],
"type": "Positive_regulation"
} |
||
18208621.s2 | Germline and somatic mutations, loss of heterozygosity (LOH), and epigenetic events such as promoter hypermethylation can lead to decreased expression of BRCA1/2 in ovarian cancers. | ovarian | {
"name": "BRCA1/2",
"pos": [
154,
160
]
} | {
"name": "ovarian cancers",
"pos": [
165,
179
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
140,
149
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
130,
138
],
"type": "Negative_regulation"
} |
||
18208621.s5 | Eighteen (37%) of the ovarian carcinomas had germline or somatic BRCA1 mutations, or epigenetic loss of BRCA1. | ovarian | {
"name": "BRCA1",
"pos": [
104,
108
]
} | {
"name": "ovarian carcinomas",
"pos": [
22,
39
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "loss",
"pos": [
96,
99
],
"type": "Negative_regulation"
} |
15382080.s11 | KTI treatment may also be beneficial for ovarian cancer patients with or at risk for peritoneal disseminated metastasis; it greatly reduces tumor burden in part by inhibiting phosphorylation of MAP kinase and PI3 kinase, leading to suppression of uPA expression. | ovarian | {
"name": "uPA",
"pos": [
247,
249
]
} | {
"name": "ovarian cancer",
"pos": [
41,
54
]
} | decreased | cancerTOnormal | causality | unidentifiable | {
"name": "expression",
"pos": [
251,
260
],
"type": "Gene_expression"
} | {
"name": "suppression",
"pos": [
232,
242
],
"type": "Negative_regulation"
} |
12006545.s11 | These results indicate that high PTEN expression enhances the sensitivity of ovarian cancer cells to irinotecan and the induction of apoptosis and the suppression of topoisomerase I activity in cancer cells are suggested as possible mechanisms attributable to high PTEN expression. | ovarian | {
"name": "topoisomerase I",
"pos": [
166,
180
]
} | {
"name": "ovarian cancer",
"pos": [
77,
90
]
} | decreased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "suppression",
"pos": [
151,
161
],
"type": "Negative_regulation"
} |
16299254.s13 | The data also show that LY294002 directly inhibits vascular endothelial growth factor (VEGF) protein expression and release from ovarian carcinoma and suggest that LY294002 blocks the VEGF signaling pathway involved in angiogenesis and vascular permeability. | ovarian | {
"name": "VEGF",
"pos": [
87,
90
]
} | {
"name": "ovarian carcinoma",
"pos": [
129,
145
]
} | decreased | cancerTOnormal | observation | unidentifiable | {
"name": "expression",
"pos": [
101,
110
],
"type": "Gene_expression"
} | {
"name": "inhibits",
"pos": [
42,
49
],
"type": "Negative_regulation"
} |
16299254.s13 | The data also show that LY294002 directly inhibits vascular endothelial growth factor (VEGF) protein expression and release from ovarian carcinoma and suggest that LY294002 blocks the VEGF signaling pathway involved in angiogenesis and vascular permeability. | ovarian | {
"name": "VEGF",
"pos": [
184,
187
]
} | {
"name": "ovarian carcinoma",
"pos": [
129,
145
]
} | decreased | cancerTOnormal | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "blocks",
"pos": [
173,
178
],
"type": "Negative_regulation"
} |
16299254.s13 | The data also show that LY294002 directly inhibits vascular endothelial growth factor (VEGF) protein expression and release from ovarian carcinoma and suggest that LY294002 blocks the VEGF signaling pathway involved in angiogenesis and vascular permeability. | ovarian | {
"name": "vascular endothelial growth factor",
"pos": [
51,
84
]
} | {
"name": "ovarian carcinoma",
"pos": [
129,
145
]
} | decreased | cancerTOnormal | observation | unidentifiable | {
"name": "expression",
"pos": [
101,
110
],
"type": "Gene_expression"
} | {
"name": "inhibits",
"pos": [
42,
49
],
"type": "Negative_regulation"
} |
21695196.s0 | Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer. | ovarian | {
"name": "HYAL-1",
"pos": [
57,
62
]
} | {
"name": "epithelial ovarian cancer",
"pos": [
68,
92
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "expression",
"pos": [
26,
35
],
"type": "Gene_expression"
} | {
"name": "elevated",
"pos": [
17,
24
],
"type": "Positive_regulation"
} |
21695196.s0 | Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer. | ovarian | {
"name": "hyaluronidase-1",
"pos": [
40,
54
]
} | {
"name": "epithelial ovarian cancer",
"pos": [
68,
92
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "expression",
"pos": [
26,
35
],
"type": "Gene_expression"
} | {
"name": "elevated",
"pos": [
17,
24
],
"type": "Positive_regulation"
} |
12759391.s1 | Lysophosphatidic acid (LPA), at concentrations present in ascitic fluid, indirectly stimulates the growth of malignant ovarian tumors by increasing the expression of vascular endothelial growth factor (VEGF) in ovarian cancer cells. | ovarian | {
"name": "vascular endothelial growth factor",
"pos": [
166,
199
]
} | {
"name": "malignant ovarian tumors",
"pos": [
109,
132
]
} | increased | normalTOcancer | causality | unidentifiable | {
"name": "expression",
"pos": [
152,
161
],
"type": "Gene_expression"
} | {
"name": "increasing",
"pos": [
137,
146
],
"type": "Positive_regulation"
} |
12759391.s1 | Lysophosphatidic acid (LPA), at concentrations present in ascitic fluid, indirectly stimulates the growth of malignant ovarian tumors by increasing the expression of vascular endothelial growth factor (VEGF) in ovarian cancer cells. | ovarian | {
"name": "VEGF",
"pos": [
202,
205
]
} | {
"name": "malignant ovarian tumors",
"pos": [
109,
132
]
} | increased | normalTOcancer | causality | unidentifiable | {
"name": "expression",
"pos": [
152,
161
],
"type": "Gene_expression"
} | {
"name": "increasing",
"pos": [
137,
146
],
"type": "Positive_regulation"
} |
12759391.s5 | Four of six cancer cell lines, including OVCAR-3, overexpressed cyclin D1 protein relative to levels in IOSE-29 cells. | ovarian | {
"name": "cyclin D1 protein",
"pos": [
64,
80
]
} | {
"name": "OVCAR-3",
"pos": [
41,
47
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "overexpressed",
"pos": [
50,
62
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
50,
62
],
"type": "Positive_regulation"
} |
12759391.s6 | LPA treatment increased cyclin D1 protein in a dose- and time-dependent manner in OVCAR-3 cells but not in IOSE-29 cells. | ovarian | {
"name": "cyclin D1 protein",
"pos": [
24,
40
]
} | {
"name": "OVCAR-3",
"pos": [
82,
88
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increased",
"pos": [
14,
22
],
"type": "Positive_regulation"
} |
||
12759391.s11 | In addition to the previously characterized indirect mechanism that increases angiogenesis via VEGF, LPA may directly increase the level of cyclin D1 in ovarian cancer cells, increasing their proliferation. | ovarian | {
"name": "cyclin D1",
"pos": [
140,
148
]
} | {
"name": "ovarian cancer",
"pos": [
153,
166
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increase",
"pos": [
118,
125
],
"type": "Positive_regulation"
} |
11280739.s6 | Cisplatin decreased XIAP protein levels and induced Akt cleavage and apoptosis in chemosensitive, but not in resistant, ovarian cancer cells. | ovarian | {
"name": "XIAP protein",
"pos": [
20,
31
]
} | {
"name": "ovarian cancer",
"pos": [
120,
133
]
} | decreased | unidentifiable | {
"name": "levels",
"pos": [
33,
38
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
10,
18
],
"type": "Negative_regulation"
} |
||
11280739.s11 | In a cell line (OVCAR-3) where basal phosphorylated Akt levels were high, XIAP overexpression failed to increase further the level of this phosphoprotein. | ovarian | {
"name": "XIAP",
"pos": [
74,
77
]
} | {
"name": "OVCAR-3",
"pos": [
16,
22
]
} | increased | unidentifiable | {
"name": "overexpression",
"pos": [
79,
92
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
79,
92
],
"type": "Positive_regulation"
} |
||
15806153.s4 | Treatment of HOSE or OCa cells with estrone or 17beta-estradiol at 10(-8) M for a period of 72 h induced significant loss of PR-A and PR-B mRNA and protein expression, with the regulation primarily controlled at the transcriptional level. | ovarian | {
"name": "PR-A",
"pos": [
125,
128
]
} | {
"name": "HOSE",
"pos": [
13,
16
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
156,
165
],
"type": "Gene_expression"
} | {
"name": "loss",
"pos": [
117,
120
],
"type": "Negative_regulation"
} |
||
15806153.s4 | Treatment of HOSE or OCa cells with estrone or 17beta-estradiol at 10(-8) M for a period of 72 h induced significant loss of PR-A and PR-B mRNA and protein expression, with the regulation primarily controlled at the transcriptional level. | ovarian | {
"name": "PR-A",
"pos": [
125,
128
]
} | {
"name": "HOSE",
"pos": [
13,
16
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "loss",
"pos": [
117,
120
],
"type": "Negative_regulation"
} |
||
15806153.s4 | Treatment of HOSE or OCa cells with estrone or 17beta-estradiol at 10(-8) M for a period of 72 h induced significant loss of PR-A and PR-B mRNA and protein expression, with the regulation primarily controlled at the transcriptional level. | ovarian | {
"name": "PR-B mRNA",
"pos": [
134,
142
]
} | {
"name": "HOSE",
"pos": [
13,
16
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "loss",
"pos": [
117,
120
],
"type": "Negative_regulation"
} |
||
15806153.s4 | Treatment of HOSE or OCa cells with estrone or 17beta-estradiol at 10(-8) M for a period of 72 h induced significant loss of PR-A and PR-B mRNA and protein expression, with the regulation primarily controlled at the transcriptional level. | ovarian | {
"name": "PR-B mRNA",
"pos": [
134,
142
]
} | {
"name": "HOSE",
"pos": [
13,
16
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
156,
165
],
"type": "Gene_expression"
} | {
"name": "loss",
"pos": [
117,
120
],
"type": "Negative_regulation"
} |
||
22142513.s1 | The expression of programmed cell death 6 (PDCD6) is known to be down-regulated in cancer cell lines and ovarian cancer tissues compared to normal cells and tissues. | ovarian | {
"name": "PDCD6",
"pos": [
43,
47
]
} | {
"name": "ovarian cancer",
"pos": [
105,
118
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "expression",
"pos": [
4,
13
],
"type": "Gene_expression"
} | {
"name": "down-regulated",
"pos": [
65,
78
],
"type": "Negative_regulation"
} |
22142513.s1 | The expression of programmed cell death 6 (PDCD6) is known to be down-regulated in cancer cell lines and ovarian cancer tissues compared to normal cells and tissues. | ovarian | {
"name": "programmed cell death 6",
"pos": [
18,
40
]
} | {
"name": "ovarian cancer",
"pos": [
105,
118
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "expression",
"pos": [
4,
13
],
"type": "Gene_expression"
} | {
"name": "down-regulated",
"pos": [
65,
78
],
"type": "Negative_regulation"
} |
19423340.s2 | The drug-resistant cell lines include ovarian cancer cell lines resistant to cisplatin, topotecan, adriamycin and paclitaxel overexpressing class III beta-tubulin, A2780TC1 and A2780TC3. | ovarian | {
"name": "class III beta-tubulin",
"pos": [
140,
161
]
} | {
"name": "ovarian cancer",
"pos": [
38,
51
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "overexpressing",
"pos": [
125,
138
],
"type": "Gene_expression"
} | {
"name": "overexpressing",
"pos": [
125,
138
],
"type": "Positive_regulation"
} |
17690890.s1 | Expression and overexpression of the epidermal growth factor receptor (EGFR) have been described in several solid tumors including bladder, breast, colorectal, NSCLC, prostate, and ovarian cancers. | ovarian | {
"name": "EGFR",
"pos": [
71,
74
]
} | {
"name": "ovarian cancers",
"pos": [
181,
195
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpression",
"pos": [
15,
28
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
15,
28
],
"type": "Positive_regulation"
} |
17690890.s1 | Expression and overexpression of the epidermal growth factor receptor (EGFR) have been described in several solid tumors including bladder, breast, colorectal, NSCLC, prostate, and ovarian cancers. | ovarian | {
"name": "epidermal growth factor receptor",
"pos": [
37,
68
]
} | {
"name": "ovarian cancers",
"pos": [
181,
195
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpression",
"pos": [
15,
28
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
15,
28
],
"type": "Positive_regulation"
} |
19097929.s6 | Increased KLF6-SV1 expression is associated with poor prognosis in prostate, lung, and ovarian cancer. | ovarian | {
"name": "KLF6-SV1",
"pos": [
10,
17
]
} | {
"name": "ovarian cancer",
"pos": [
87,
100
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "expression",
"pos": [
19,
28
],
"type": "Gene_expression"
} | {
"name": "Increased",
"pos": [
0,
8
],
"type": "Positive_regulation"
} |
8431895.s4 | The malignant ovarian epithelial phenotype has been associated with (1) autocrine growth stimulation by transforming growth factor-alpha, (2) loss of autocrine growth inhibition by transforming growth factor-beta, (3) mutation or amplification of ras in 2-12% of cases, (4) amplification of myc in 23% of specimens, (5) expression of fms in 56% of cases with potential autocrine stimulation by macrophage colony stimulating factor, (6) paracrine stimulation by macrophage products including interleukin-1, interleukin-6 and tumor necrosis factor, (7) overexpression of c-erbB-2 (HER-2/neu) in 30% of cases, and (8) mutation with consequent overexpression of p53 in 50% of advanced ovarian cancers. | ovarian | {
"name": "HER-2/neu",
"pos": [
579,
587
]
} | {
"name": "ovarian cancers",
"pos": [
681,
695
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpression",
"pos": [
551,
564
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
551,
564
],
"type": "Positive_regulation"
} |
8431895.s4 | The malignant ovarian epithelial phenotype has been associated with (1) autocrine growth stimulation by transforming growth factor-alpha, (2) loss of autocrine growth inhibition by transforming growth factor-beta, (3) mutation or amplification of ras in 2-12% of cases, (4) amplification of myc in 23% of specimens, (5) expression of fms in 56% of cases with potential autocrine stimulation by macrophage colony stimulating factor, (6) paracrine stimulation by macrophage products including interleukin-1, interleukin-6 and tumor necrosis factor, (7) overexpression of c-erbB-2 (HER-2/neu) in 30% of cases, and (8) mutation with consequent overexpression of p53 in 50% of advanced ovarian cancers. | ovarian | {
"name": "c-erbB-2",
"pos": [
569,
576
]
} | {
"name": "ovarian cancers",
"pos": [
681,
695
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpression",
"pos": [
551,
564
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
551,
564
],
"type": "Positive_regulation"
} |
16086871.s8 | pshRNA-Survivin could reduce the expression of Survivin gene, and induce apoptosis of SKOV3 and SKOV3/ADM cells. | ovarian | {
"name": "Survivin gene",
"pos": [
47,
59
]
} | {
"name": "SKOV3",
"pos": [
86,
90
]
} | decreased | cancerTOnormal | observation | unidentifiable | {
"name": "expression",
"pos": [
33,
42
],
"type": "Gene_expression"
} | {
"name": "reduce",
"pos": [
22,
27
],
"type": "Negative_regulation"
} |
19638582.s4 | Three recent articles support a model in which, in the absence of mutations in the Hh pathway, Hh ligands expressed by a subset of epithelial cancers, including colon, pancreatic, and ovarian cancer, promote tumor growth indirectly by activating Hh signaling in the surrounding stroma, which, in turn, provides a more favorable environment for tumor growth. | ovarian | {
"name": "Hh",
"pos": [
246,
247
]
} | {
"name": "ovarian cancer",
"pos": [
184,
197
]
} | increased | normalTOcancer | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "activating",
"pos": [
235,
244
],
"type": "Positive_regulation"
} |
19419758.s1 | We have previously shown that TCEAL7 (transcription elongation factor A (SII)-like 7) is epigenetically down-regulated in the majority of epithelial ovarian cancers. | ovarian | {
"name": "TCEAL7",
"pos": [
30,
35
]
} | {
"name": "epithelial ovarian cancers",
"pos": [
138,
163
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "down-regulated",
"pos": [
104,
117
],
"type": "Negative_regulation"
} |
19419758.s1 | We have previously shown that TCEAL7 (transcription elongation factor A (SII)-like 7) is epigenetically down-regulated in the majority of epithelial ovarian cancers. | ovarian | {
"name": "transcription elongation factor A (SII)-like 7",
"pos": [
38,
83
]
} | {
"name": "epithelial ovarian cancers",
"pos": [
138,
163
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "down-regulated",
"pos": [
104,
117
],
"type": "Negative_regulation"
} |
17045920.s0 | Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. | ovarian | {
"name": "AKT",
"pos": [
169,
171
]
} | {
"name": "ovarian cancer",
"pos": [
194,
207
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "activation",
"pos": [
155,
164
],
"type": "Positive_regulation"
} |
||
17045920.s0 | Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. | ovarian | {
"name": "P70S6K1",
"pos": [
177,
183
]
} | {
"name": "ovarian cancer",
"pos": [
194,
207
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "activation",
"pos": [
155,
164
],
"type": "Positive_regulation"
} |
||
17045920.s1 | The epidermal growth factor (EGF) and EGF receptor (EGFR) family are often overexpressed in various human cancers including ovarian cancer. | ovarian | {
"name": "EGFR",
"pos": [
52,
55
]
} | {
"name": "ovarian cancer",
"pos": [
124,
137
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
75,
87
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
75,
87
],
"type": "Positive_regulation"
} |
17045920.s1 | The epidermal growth factor (EGF) and EGF receptor (EGFR) family are often overexpressed in various human cancers including ovarian cancer. | ovarian | {
"name": "epidermal growth factor",
"pos": [
4,
26
]
} | {
"name": "ovarian cancer",
"pos": [
124,
137
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
75,
87
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
75,
87
],
"type": "Positive_regulation"
} |
17045920.s1 | The epidermal growth factor (EGF) and EGF receptor (EGFR) family are often overexpressed in various human cancers including ovarian cancer. | ovarian | {
"name": "EGF",
"pos": [
29,
31
]
} | {
"name": "ovarian cancer",
"pos": [
124,
137
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
75,
87
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
75,
87
],
"type": "Positive_regulation"
} |
17045920.s1 | The epidermal growth factor (EGF) and EGF receptor (EGFR) family are often overexpressed in various human cancers including ovarian cancer. | ovarian | {
"name": "EGF receptor",
"pos": [
38,
49
]
} | {
"name": "ovarian cancer",
"pos": [
124,
137
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
75,
87
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
75,
87
],
"type": "Positive_regulation"
} |
17045920.s9 | This study demonstrates a novel mechanism of EGF-induced VEGF and HIF-1alpha expression through production of H2O2 and activation of AKT and p70S6K1 in human ovarian cancer cells. | ovarian | {
"name": "p70S6K1",
"pos": [
141,
147
]
} | {
"name": "ovarian cancer",
"pos": [
158,
171
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "activation",
"pos": [
119,
128
],
"type": "Positive_regulation"
} |
||
17045920.s9 | This study demonstrates a novel mechanism of EGF-induced VEGF and HIF-1alpha expression through production of H2O2 and activation of AKT and p70S6K1 in human ovarian cancer cells. | ovarian | {
"name": "AKT",
"pos": [
133,
135
]
} | {
"name": "ovarian cancer",
"pos": [
158,
171
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "activation",
"pos": [
119,
128
],
"type": "Positive_regulation"
} |
||
10419053.s1 | Human folate receptor alpha (FRalpha) is a folate-binding protein that is selectively overexpressed in ovarian carcinoma and has been regarded as a suitable target antigen for immunotherapy purposes. | ovarian | {
"name": "Human folate receptor alpha",
"pos": [
0,
26
]
} | {
"name": "ovarian carcinoma",
"pos": [
103,
119
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
86,
98
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
86,
98
],
"type": "Positive_regulation"
} |
10419053.s1 | Human folate receptor alpha (FRalpha) is a folate-binding protein that is selectively overexpressed in ovarian carcinoma and has been regarded as a suitable target antigen for immunotherapy purposes. | ovarian | {
"name": "FRalpha",
"pos": [
29,
35
]
} | {
"name": "ovarian carcinoma",
"pos": [
103,
119
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
86,
98
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
86,
98
],
"type": "Positive_regulation"
} |
7696178.s0 | Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. | ovarian | {
"name": "CIP1/WAF1",
"pos": [
45,
53
]
} | {
"name": "ovarian cancer",
"pos": [
100,
113
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "induce",
"pos": [
38,
43
],
"type": "Positive_regulation"
} |
||
7696178.s10 | OVCA420, a cell line that is dramatically growth inhibited by TGF beta 1, significantly induced CIP1 expression in response to TGF beta 1. | ovarian | {
"name": "CIP1",
"pos": [
96,
99
]
} | {
"name": "OVCA420",
"pos": [
0,
6
]
} | increased | cancerTOnormal | observation | unidentifiable | {
"name": "expression",
"pos": [
101,
110
],
"type": "Gene_expression"
} | {
"name": "induced",
"pos": [
88,
94
],
"type": "Positive_regulation"
} |
17118344.s8 | Furthermore, by using ovarian cancer cell lines expressing dominant-negative CHK2 and CHK2-knockout HCT116 cells, we found that CHK2 activation contributes to the control of S and G2/M cell cycle arrests, but not chemosensitivity to irofulven. | ovarian | {
"name": "CHK2",
"pos": [
128,
131
]
} | {
"name": "ovarian cancer",
"pos": [
22,
35
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "activation",
"pos": [
133,
142
],
"type": "Positive_regulation"
} |
||
19649288.s5 | GSK3 inhibition using 6-bromoindirubin-3'-oxime suppressed hTERT expression, telomerase activity and telomere length in several cancer cell lines and growth and hTERT expression in ovarian cancer xenografts. | ovarian | {
"name": "hTERT",
"pos": [
59,
63
]
} | {
"name": "ovarian cancer",
"pos": [
181,
194
]
} | decreased | cancerTOnormal | observation | unidentifiable | {
"name": "expression",
"pos": [
65,
74
],
"type": "Gene_expression"
} | {
"name": "suppressed",
"pos": [
48,
57
],
"type": "Negative_regulation"
} |
15913739.s8 | Single-chain antibody-mediated inhibition of Bcl-2 in SKOV3 cells was associated with increased growth rates and more rapid cell cycle progression. | ovarian | {
"name": "Bcl-2",
"pos": [
45,
49
]
} | {
"name": "SKOV3",
"pos": [
54,
58
]
} | decreased | normalTOcancer | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "inhibition",
"pos": [
31,
40
],
"type": "Negative_regulation"
} |
15913739.s9 | Treatment with cisplatin resulted in more cells accumulating in S phase in Bcl-2-overexpressing SKOV3 cells, while the inhibition of Bcl-2 abolished delayed entry into G2M phase without affecting cisplatin-induced apoptosis. | ovarian | {
"name": "Bcl-2",
"pos": [
133,
137
]
} | {
"name": "SKOV3",
"pos": [
96,
100
]
} | decreased | normalTOcancer | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "inhibition",
"pos": [
119,
128
],
"type": "Negative_regulation"
} |
18723500.s8 | The drop in PCho levels following FASN inhibition was confirmed in SKOV-3 ovarian cancer cells treated with Orlistat and in MCF-7 breast cancer cells treated with Orlistat as well as cerulenin. | ovarian | {
"name": "FASN",
"pos": [
34,
37
]
} | {
"name": "ovarian cancer",
"pos": [
74,
87
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "inhibition",
"pos": [
39,
48
],
"type": "Negative_regulation"
} |
||
14739059.s7 | Serum alphaFP and betaHCG are very useful in the preoperative evaluation and management of nondysgerminomatous ovarian germ cell tumors, whereas elevated serum inhibin levels can be detected in patients with granulosa cell tumors of the ovary. | ovarian | {
"name": "inhibin",
"pos": [
160,
166
]
} | {
"name": "ovarian germ cell tumors",
"pos": [
111,
134
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "elevated",
"pos": [
145,
152
],
"type": "Positive_regulation"
} |
14563607.s2 | The authors report one case in a 43-year-old woman, the initial interpretation of which, based on pleural and peritoneal exudate, showed suspected latero-uterine mass and significant elevated serum CA 125 level, mimicking disseminated ovarian carcinoma. | ovarian | {
"name": "CA 125",
"pos": [
198,
203
]
} | {
"name": "ovarian carcinoma",
"pos": [
235,
251
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "elevated",
"pos": [
183,
190
],
"type": "Positive_regulation"
} |
19876919.s7 | Pak1, p-Pak1 and p-Pak2 were overexpressed in ovarian cancer cell lines, and clinical samples of ovarian cancers were compared with benign ovarian lesions/inclusion cysts. | ovarian | {
"name": "Pak1",
"pos": [
0,
3
]
} | {
"name": "ovarian cancers",
"pos": [
97,
111
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
29,
41
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
29,
41
],
"type": "Positive_regulation"
} |
19876919.s7 | Pak1, p-Pak1 and p-Pak2 were overexpressed in ovarian cancer cell lines, and clinical samples of ovarian cancers were compared with benign ovarian lesions/inclusion cysts. | ovarian | {
"name": "p-Pak1",
"pos": [
6,
11
]
} | {
"name": "ovarian cancers",
"pos": [
97,
111
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
29,
41
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
29,
41
],
"type": "Positive_regulation"
} |
19876919.s7 | Pak1, p-Pak1 and p-Pak2 were overexpressed in ovarian cancer cell lines, and clinical samples of ovarian cancers were compared with benign ovarian lesions/inclusion cysts. | ovarian | {
"name": "p-Pak2",
"pos": [
17,
22
]
} | {
"name": "ovarian cancers",
"pos": [
97,
111
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
29,
41
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
29,
41
],
"type": "Positive_regulation"
} |
19876919.s14 | Conversely, ectopic Pak1 overexpression enhanced ovarian cancer cell migration and invasion in a kinase-dependent manner, along with increased p38 activation. | ovarian | {
"name": "Pak1",
"pos": [
20,
23
]
} | {
"name": "ovarian cancer",
"pos": [
49,
62
]
} | increased | normalTOcancer | causality | unidentifiable | {
"name": "overexpression",
"pos": [
25,
38
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
25,
38
],
"type": "Positive_regulation"
} |
19876919.s14 | Conversely, ectopic Pak1 overexpression enhanced ovarian cancer cell migration and invasion in a kinase-dependent manner, along with increased p38 activation. | ovarian | {
"name": "p38",
"pos": [
143,
145
]
} | {
"name": "ovarian cancer",
"pos": [
49,
62
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increased",
"pos": [
133,
141
],
"type": "Positive_regulation"
} |
18436522.s0 | Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice. | ovarian | {
"name": "vesicular stomatitis virus matrix protein",
"pos": [
115,
155
]
} | {
"name": "ovarian cancer",
"pos": [
50,
63
]
} | increased | cancerTOnormal | causality | unidentifiable | {
"name": "transferred",
"pos": [
103,
113
],
"type": "Gene_expression"
} | {
"name": "transferred",
"pos": [
103,
113
],
"type": "Positive_regulation"
} |
16370564.s0 | Coexistence of Graves' disease and benign struma ovarii in a patient with marked ascites and elevated CA-125 levels. | ovarian | {
"name": "CA-125",
"pos": [
102,
107
]
} | {
"name": "benign struma ovarii",
"pos": [
35,
54
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "elevated",
"pos": [
93,
100
],
"type": "Positive_regulation"
} |
21340838.s1 | Amplification or overexpression of the c-erbB-2 oncogene (also known as HER-2, neu) is a frequent event in many types of human cancer including 20-30% of ovarian cancers where it characterizes a group of patients with poor prognosis (1,2). | ovarian | {
"name": "c-erbB-2 oncogene",
"pos": [
39,
55
]
} | {
"name": "ovarian cancers",
"pos": [
154,
168
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpression",
"pos": [
17,
30
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
17,
30
],
"type": "Positive_regulation"
} |
20036116.s3 | The HER2 overexpressing human SKOV-3 ovarian tumour cell line was used for in vitro experiments and as xenograft model in nude athymic mice. | ovarian | {
"name": "HER2",
"pos": [
4,
7
]
} | {
"name": "ovarian tumour",
"pos": [
37,
50
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "overexpressing",
"pos": [
9,
22
],
"type": "Gene_expression"
} | {
"name": "overexpressing",
"pos": [
9,
22
],
"type": "Positive_regulation"
} |
14701673.s9 | Transfection with the kinase-inactive mutant of Akt or TM of FKHRL1 induced the activity of the Fas ligand promoter in Caov-3 cells. | ovarian | {
"name": "Fas ligand promoter",
"pos": [
96,
114
]
} | {
"name": "Caov-3",
"pos": [
119,
124
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "induced",
"pos": [
68,
74
],
"type": "Positive_regulation"
} |